Calithera Biosciences, Inc.

Calithera Biosciences, Inc. is a biopharmaceutical company located in South San Francisco, California, in the United States. The company is associated with the discovery and development of small-molecule therapeutic candidates, with a focus on cancer biology and tumor metabolism. Its corporate identity is tied to the South San Francisco life-sciences cluster, one of the world's densest concentrations of biotechnology research and development activity. As a commercial entity, Calithera operates in the biopharmaceutical sector, where value is created through preclinical research, clinical trials, regulatory interactions, and, where successful, commercialization of approved medicines. The company's public-facing brand is built around its scientific platform and pipeline rather than consumer products, and its website serves as the primary channel for corporate and scientific communication. The evidence available for this dossier is limited to a Wikidata entry and a seed description, both of which identify Calithera as a company in South San Francisco, United States. No founding date, founder names, ownership structure, stock listing, or specific product names are provided in the supplied evidence, and those details are therefore left unstated rather than inferred. The dossier should be treated as a minimal, evidence-bound record that can be expanded as additional verified information becomes available.

Calithera Biosciences is identified in the available evidence as a company in South San Francisco, United States. The supplied sources do not provide a founding date, founding team, or a chronological account of the company's development. What can be stated on the basis of the evidence is its location and its status as a company. A full corporate history — including research programs, clinical milestones, financing events, partnerships, and any changes in ownership or listing status — cannot be written from the evidence provided and is therefore omitted rather than reconstructed from assumption.

• 2021-05-17

  Antengene and Calithera enter global CB-708 licensing agreement[3]德琪医药与Calithera达成CB-708全球授权协议prnasia.com

  Reported: 2021-05-17

  Antengene and Calithera announced an exclusive licensing agreement for the global development and commercialization of CB-708 (ATG-037). Antengene will lead development and commercialization; Calithera is eligible for an upfront payment, milestone payments, and tiered royalties.

• 2020-07-14

  Calithera appoints Scott Garland to its board[4]Calithera 任命 Scott Garland 为董事会成员biospace.com

  Reported: 2020-07-14

  Calithera Biosciences announced Scott Garland's appointment to its board of directors.

1. 1Calithera (United States) — Wikidatawikidata.org
2. 2Calithera official websitecalithera.com
3. 3德琪医药与Calithera达成CB-708全球授权协议prnasia.com
4. 4Calithera 任命 Scott Garland 为董事会成员biospace.com